Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Spare Receptors01:30

Spare Receptors

Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Urinary proteomics identifies unique signatures in infants with congenital diaphragmatic hernia and tetralogy of Fallot.

Pediatric research·2026
Same author

Aberrant STAT signaling and T cell dysregulation define a targetable pediatric sepsis endotype.

The Journal of clinical investigation·2026
Same author

Cross-species comparison of platelet proteomes reveals developmentally regulated metabolic and inflammatory changes.

Blood vessels, thrombosis & hemostasis·2026
Same author

Metabolic and transcriptional plasticity supports CD8<sup>+</sup> T cell resilience and anti-tumor immunity under nutrient stress.

Immunity·2026
Same author

SPTBN2 promotes an immunosuppressive tumor microenvironment and cross-resistance to anti-cancer therapies.

bioRxiv : the preprint server for biology·2026
Same author

Multi-omic profiling of early pregnancy small and large plasma extracellular vesicles reveals placental, metabolic, and structural adaptation signatures.

bioRxiv : the preprint server for biology·2026

関連する実験動画

Updated: Jul 6, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

AraCの調節タンパク質変異体で,効果因子特異性が変化している.

Shuang-Yan Tang1, Hossein Fazelinia, Patrick C Cirino

  • 1Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.

Journal of the American Chemical Society
|March 22, 2008
PubMed
まとめ

研究者は,AraC調節タンパク質をL-アラビノースではなくD-アラビノースに反応するように設計し,新しい遺伝子スイッチを作成しました. この突破は,代謝工学のアプリケーションの正確な制御を可能にします.

科学分野:

  • 分子生物学は分子生物学である.
  • 合成生物学 合成生物学とは
  • 微生物工学とは

背景:

  • AraCタンパク質は,Escherichia coliのアラオペロンを調節し,通常はL-アラビノースに反応する.
  • 変化したエフェクタ特異性のための転写因子を設計することは,合成生物学にとって極めて重要です.

研究 の 目的:

  • AraCタンパク質を設計して,D-アラビノースに反応して転写を活性化させ,L-アラビノースからのエフェクター特異性を切り替える.
  • 生体内の遺伝子調節と代謝工学のための新しい分子ツールを開発する.

主な方法:

  • ランダム化された結合ポケット残留物による2つのAraCミュータントライブラリの構築とスクリーニング.
  • 二重スクリーニングのためのGFPレポーターによる光活性化細胞分類 (FACS) を利用する.
  • 様々な砂糖に対する突然変異の反応をテストし,FucPトランスポーターでD-アラビノース誘導を最適化.

主要な成果:

  • D-アラビノース特異の転写活性化を示す特定されたAraC変異体,効果因子の不在で緊密な抑制を保持した.
  • L-アラビノースと他の試験された砂糖は,エンジニアリングされた突然変異を誘導しないことを確認しました.
  • FucPトランスポーターの共同発現により,ミリモラー範囲 (0.1 mM) のD-アラビノース誘導を達成した.

さらに関連する動画

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

関連する実験動画

Last Updated: Jul 6, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

結論:

  • ダブルスクリーニングは,AraC.のような調節タンパク質の誘発特異性を変化させる強力な方法である.
  • エンジニアリングされたAraC変種は,カスタマイズされたin vivo分子レポーターと遺伝子スイッチの作成に向けた重要な進歩を表しています.
  • これらのエンジニアリングされたタンパク質は,代謝工学と精密な生物学的制御システムにおける潜在的な応用があります.